SpyBiotech Announces the Completion of Enrollment in Phase I Trial of SPYVLP01 Targeting Human Cytomegalovirus (HCMV)
Oxford, UK and Cambridge, MA – (July 23, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced today the completion of enrollment in its Phase I trial of SPYVLP01, a vaccine candidate targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology. […]